Skip to main content
. 2022 Dec 16;75(2):293–304. doi: 10.1002/art.42335

Figure 2.

Figure 2

Flow chart depicting patient distribution and study disposition for a randomized, placebo‐controlled, double‐blind trial assessing pegloticase plus methotrexate (MTX) versus pegloticase plus placebo (PBO) cotreatment for uncontrolled gout. * = 1 patient in each treatment group discontinued MTX/PBO but continued to receive biweekly pegloticase infusions. † = withdrawal due to COVID‐19 concerns, not infection. ITT = intent‐to‐treat; mITT = modified intent‐to‐treat.